Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Metastatic pancreatic adenocarcinoma histological proved
FOLFIRINOX chemotherapy-ineligible patient and going to receive first-line metastatic chemotherapy with gemcitabine monotherapy
Tumor material allowing assessment of GEMCore status (i.e. FFPE block with tumor cellularity ≥ 10%);
Life expectancy \> 2 months;
Measurable target according to RECIST 1.1 criteria;
No previous treatment in metastatic situation;
Age ≥ 18 years;
Patient not opposed to study participation;
Affiliation to a social security system, or beneficiary of such a scheme.

Contraindication to Gemcitabine treatment;
ECOG performance status ≥ 3;
Person in emergency situation or unable to express non-opposition;
Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice);
Unable to undergo medical follow-up for geographical, social or psychological reasons.

Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients